Wen et al., 2019 also confirmed EGCG derivative Y6 reversed doxorubicin resistance in hepatoma cells through competitively inhibiting efflux pump activity of ABC transporter. Additionally, Chen et al., 2014 found EGCG could kill hepatoma cells synergically with doxorubicin through inhibiting doxorubicin-induced autophagy. Here, ABCG2 is linked to hepatocellular carcinoma.